Changeflow GovPing Pharma & Drug Safety Compositions and Methods for Treating Mycobacte...
Routine Notice Added Final

Compositions and Methods for Treating Mycobacterium Infections

Favicon for changeflow.com USPTO Patent Applications - Pharma (A61K)
Published
Detected
Email

Summary

USPTO published patent application US20260091043A1 for compositions and methods treating infections caused by Mycobacteriaceae family pathogens, including those causing tuberculosis. Inventors John David Wild, Jeremy Joseph Yang, and Sean Ekins filed the application on September 20, 2023. The application claims priority to Application No. 19113756 and covers novel therapeutic approaches to bacterial infections.

What changed

USPTO published patent application US20260091043A1 titled 'Compositions and Methods for Treating Mycobacterium Infections.' The application discloses treatments for infections caused by pathogenic bacteria within the Mycobacteriaceae family, with CPC classifications A61K 31/609, A61P 31/04, and A61P 31/06 indicating pharmaceutical compositions for antibacterial and anti-tubercular applications. The application was filed on September 20, 2023, under Application No. 19113756 and published on April 2, 2026.

Patent applications do not impose compliance obligations on third parties. Drug manufacturers and pharmaceutical researchers may review this publication to understand potential new therapeutic approaches being developed. Healthcare providers and biotechnology companies should note this disclosure when conducting related R&D to avoid potential infringement issues during product development.

Archived snapshot

Apr 3, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

COMPOSITIONS AND METHODS FOR TREATING MYCOBACTERIUM INFECTIONS

Application US20260091043A1 Kind: A1 Apr 02, 2026

Inventors

John David WILD, Jeremy Joseph YANG, Sean EKINS

Abstract

Described herein are treatments of infections and diseases caused by pathogenic bacteria, including the treatment of infections and diseases caused by Mycobactertaceae.

CPC Classifications

A61K 31/609 A61P 31/04 A61P 31/06

Filing Date

2023-09-20

Application No.

19113756

View original document →

Get daily alerts for USPTO Patent Applications - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
USPTO
Published
April 2nd, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260091043A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology 6211 Healthcare Providers
Activity scope
Biopharmaceutical R&D Drug Development Medical Treatment Licensing
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Biotechnology Healthcare

Get alerts for this source

We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.